



## **EFPIA Disclosure Code 2016 Self-Certification Scheme**

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Bayer AG works provide the Pharmaceutical Industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharma companies work with scientists and healthcare professionals. These collaborations are essential in addressing patient needs. Industry and healthcare professionals collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with healthcare professionals and organisations meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharma companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

Bayer AG hereby confirms that its disclosures of transfers of value (ToVs) to HCPs and HCOs made in 2015 have been reported in application of the EFPIA Disclosure Code following key principles:

### **Disclosure quality**

Bayer AG certifies that:

- Its disclosures are made in each country where it operates;
- Its disclosures include direct and indirect ToVs, as defined in the codes and associated guidance issued by EFPIA;
- Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

### **Methodology used for the collection and organisation of ToVs is in line with the EFPIA Disclosure Code's requirements and applicable codes**

Bayer AG certifies that:

- Data collection complies with the requirements of the EFPIA Disclosure Code;
- Actions were taken to seek consent from HCPs and HCOs (each as defined in the EFPIA Disclosure Code), where applicable.

**Aggregate disclosures are limited to Research and Development ToVs and such ToVs that cannot be disclosed on an individual basis for legal reasons**



Bayer AG certifies that aggregate disclosure is limited to the following topics:

- Research and Development Transfers of Value (as defined in the EFPIA Disclosure Code);
- Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;
  
- If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

### Seeking the consent of Recipients

Bayer AG certifies that it has used all reasonable steps for the purpose of obtaining consent to individual disclosure where such consent is required by applicable law.

Bayer AG

Berlin,

A blue ink signature of Dieter Weinand, consisting of a stylized 'D' followed by a horizontal line and a small flourish.

**Dieter Weinand**

*Member of the Board of Management  
President Pharmaceuticals*

Berlin, 3/6/2016

A blue ink signature of Dr. Stefan Gehring, written in a cursive style.

**Dr. Stefan Gehring**

*Law, Patents and Compliance  
Business Partner Pharmaceuticals*